Prophylactic Antibiotics for Manual Removal of Retained Placenta in Vaginal Birth: a Randomized Controlled Trial
Primary Purpose
Endometritis
Status
Unknown status
Phase
Not Applicable
Locations
Israel
Study Type
Interventional
Intervention
Antibiotic prophylaxis
Ampicillin
Gentamycin
Clindamycin
Sponsored by
About this trial
This is an interventional treatment trial for Endometritis
Eligibility Criteria
Inclusion Criteria:
- suspected retained placenta
Exclusion Criteria:
- Intrapartum fever
Sites / Locations
- Hadassah Medical Organization
Arms of the Study
Arm 1
Arm 2
Arm Type
Active Comparator
No Intervention
Arm Label
Antibiotic prophylaxis
No treatment
Arm Description
antibiotic prophylaxis as following: 24 hours coverage with Ampicillin 2 grams*4, Gentamycin 240 mg*1, Clindamycin 600 mg*3
No antibiotics
Outcomes
Primary Outcome Measures
Endometritis rate
Secondary Outcome Measures
Puerperal fever
Full Information
NCT ID
NCT01945450
First Posted
September 15, 2013
Last Updated
November 26, 2013
Sponsor
Hadassah Medical Organization
1. Study Identification
Unique Protocol Identification Number
NCT01945450
Brief Title
Prophylactic Antibiotics for Manual Removal of Retained Placenta in Vaginal Birth: a Randomized Controlled Trial
Official Title
Prophylactic Antibiotics for Manual Removal of Retained Placenta in Vaginal Birth
Study Type
Interventional
2. Study Status
Record Verification Date
August 2013
Overall Recruitment Status
Unknown status
Study Start Date
January 2014 (undefined)
Primary Completion Date
September 2016 (Anticipated)
Study Completion Date
undefined (undefined)
3. Sponsor/Collaborators
Responsible Party, by Official Title
Sponsor
Name of the Sponsor
Hadassah Medical Organization
4. Oversight
Data Monitoring Committee
Yes
5. Study Description
Brief Summary
Background: There is scarce evidence regarding the necessity of antibiotic prophylaxis in manual revision of the uterus after labor in cases of residual placenta.
Methods: a randomized control trial in which parturients for which the placenta was not separated or there is a suspected residual placenta will be divided randomly to two groups: (1) Revision of uterus or Manual lysis without antibiotic prophylaxis; (2) Revision of uterus or Manual lysis with antibiotic prophylaxis as following: 24 hours coverage with Ampicillin 2 grams*4, Gentamycin 240 mg*1, Clindamycin 600 mg*3. In cases of allergy to Penicillin the antibiotic regimen will be: Gentamycin 240 mg*1, Clindamycin 600 mg*3.
Outcomes: Puerperal fever, endometritis, length of hospitalization after labor, recurrent hospitalization in the first 2 weeks after discharge.
6. Conditions and Keywords
Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Endometritis
7. Study Design
Primary Purpose
Treatment
Study Phase
Not Applicable
Interventional Study Model
Parallel Assignment
Masking
None (Open Label)
Allocation
Randomized
Enrollment
300 (Anticipated)
8. Arms, Groups, and Interventions
Arm Title
Antibiotic prophylaxis
Arm Type
Active Comparator
Arm Description
antibiotic prophylaxis as following: 24 hours coverage with Ampicillin 2 grams*4, Gentamycin 240 mg*1, Clindamycin 600 mg*3
Arm Title
No treatment
Arm Type
No Intervention
Arm Description
No antibiotics
Intervention Type
Drug
Intervention Name(s)
Antibiotic prophylaxis
Intervention Description
antibiotic prophylaxis as following: 24 hours coverage with Ampicillin 2 grams*4, Gentamycin 240 mg*1, Clindamycin 600 mg*3
Intervention Type
Drug
Intervention Name(s)
Ampicillin
Intervention Type
Drug
Intervention Name(s)
Gentamycin
Intervention Type
Drug
Intervention Name(s)
Clindamycin
Primary Outcome Measure Information:
Title
Endometritis rate
Time Frame
3 years
Secondary Outcome Measure Information:
Title
Puerperal fever
Time Frame
3 years
10. Eligibility
Sex
Female
Minimum Age & Unit of Time
15 Years
Maximum Age & Unit of Time
50 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria:
suspected retained placenta
Exclusion Criteria:
Intrapartum fever
Central Contact Person:
First Name & Middle Initial & Last Name or Official Title & Degree
Hadas Lamnerg, MD
Phone
: 00 972 2 6777572
Email
lhadas@hadassah.org.il
Facility Information:
Facility Name
Hadassah Medical Organization
City
Jerusalem
Country
Israel
12. IPD Sharing Statement
Learn more about this trial
Prophylactic Antibiotics for Manual Removal of Retained Placenta in Vaginal Birth: a Randomized Controlled Trial
We'll reach out to this number within 24 hrs